Status:
COMPLETED
Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension
Lead Sponsor:
Mylan Bertek Pharmaceuticals
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study was to determine if nebivolol is superior to placebo for the treatment of elevated blood pressure in Black patients with mild to moderate hypertension.
Detailed Description
This study was a Phase II, 12-week multicenter, randomized, double-blind, parallel group, placebo-controlled study of nebivolol over a range of doses in Black patients with mild to moderate hypertensi...
Eligibility Criteria
Inclusion
- Black adults with an average sitting diastolic blood pressure of greater then or equal to 95 mmHg and less then or equal to 109 mmHg at baseline.
Exclusion
- Recent myocardial infarction or stroke
- Contraindication to beta-blocker therapy
Key Trial Info
Start Date :
November 1 2001
Trial Type :
INTERVENTIONAL
End Date :
August 1 2003
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00145236
Start Date
November 1 2001
End Date
August 1 2003
Last Update
September 14 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mylan Pharmaceuticals Inc.
Morgantown, West Virginia, United States, 26505